Pα+ Psychedelic Bulletin #205: AbbVie Eyes Gilgamesh; Psychedelics Use Increases in U.S.; FDA Moves to Ban Kraton Compound 7-OH; What Is Sinema Selling?

On Wednesday, Bloomberg became the first to publicly report on a rumour that has been working its way around the field in the past few weeks: AbbVie is apparently in talks to acquire Gilgamesh Pharmaceuticals in a transaction that would value the company at around $1 billion The authors of the Bloomberg piece say the deal highlights “growing takeover interest in the sector”.

Source